Your Cute Rubber Duck May Be a Haven for Bacteria
A study of bath toys found the water inside yellow ducks swimming with microbes, including bacteria often associated with hospital infections. (Source: NYT Health)
Source: NYT Health - March 28, 2018 Category: Consumer Health News Authors: CEYLAN YEGINSU Tags: Bacteria Toys Biofilms and Microbiomes (Journal) Polymers University of Illinois Swiss Federal Institute of Aquatic Science and Technology, ETH Zurich Source Type: news

Reva touts first implant of Fantom Encore bioresorbable scaffold in Switzerland
Reva Medical (ASX:RVA) announced today that the company’s Fantom Encore bioresorbable vascular scaffold was used for the first time in Switzerland. The sirolimus-eluting device, which is made from Reva’s proprietary Tyrocore polymer, features a 95-micron strut profile and x-ray visibility. Get the full story at our sister site, Drug Delivery Business News. The post Reva touts first implant of Fantom Encore bioresorbable scaffold in Switzerland appeared first on MassDevice. (Source: Mass Device)
Source: Mass Device - March 28, 2018 Category: Medical Devices Authors: Sarah Faulkner Tags: Drug-Device Combinations Implants Pharmaceuticals Vascular Wall Street Beat Reva Medical Inc. Source Type: news

Roche shares drop after deaths of patients taking Hemlibra
ZURICH (Reuters) - Swiss drugmaker Roche's shares dropped on Wednesday after it told U.S.-based haemophilia advocacy groups that five patients treated with its medicine Hemlibra had died, while maintaining that the therapy was not the cause of the deaths. (Source: Reuters: Health)
Source: Reuters: Health - March 28, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

Tokyo court rejects Shire claim against Roche hemophilia drug
ZURICH (Reuters) - A Tokyo court has ruled that Shire's claim against Swiss drugmaker Roche's new Hemlibra hemophilia medicine should be dismissed, Roche's Japanese subsidiary Chugai said on Wednesday, helping to clear up legal uncertainty over the prospective blockbuster medicine. (Source: Reuters: Health)
Source: Reuters: Health - March 28, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

Study: Bathtub toys harbor bacteria, fungal species
The rubber ducky, those yellow bath-time toys used to entertain kids, contained high numbers of bacteria and fungal species, according to a study in Switzerland. (Source: Health News - UPI.com)
Source: Health News - UPI.com - March 27, 2018 Category: Consumer Health News Source Type: news

The Adorable Rubber Ducky Is Actually a Haven for Nasty Bacteria, Scientists Say
(BERN, Switzerland) — Scientists now have the dirt on the rubber ducky: Those cute yellow bath-time toys are — as some parents have long suspected — a haven for nasty bugs. Swiss and American researchers counted the microbes swimming inside the toys and say the murky liquid released when ducks were squeezed contained “potentially pathogenic bacteria” in four out of the five toys studied. The bacteria found included Legionella and Pseudomonas aeruginosa, a bacterium that is “often implicated in hospital-acquired infections.” The study by the Swiss Federal Institute of Aquatic Scienc...
Source: TIME: Health - March 27, 2018 Category: Consumer Health News Authors: Frank Jordans and Jamey Keaten / AP Tags: Uncategorized APH healthytime onetime public health Source Type: news

Your rubber duck is riddled with bacteria
Researchers from Swiss Federal Institute of Aquatic Science and Technology found toys that can squirt water can contain pathogens, including drug-resistant superbugs, that can be deadly. (Source: the Mail online | Health)
Source: the Mail online | Health - March 27, 2018 Category: Consumer Health News Source Type: news

Hormone treatment burns post-menopausal belly fat
Women who take hormone replacement therapies to ease the symptoms of menopause weigh slightly less and have significantly less belly fat - so long as they keep up the drugs, a new Swiss study reveals. (Source: the Mail online | Health)
Source: the Mail online | Health - March 27, 2018 Category: Consumer Health News Source Type: news

Beware of your rubber duck: The popular bathroom companion is riddled with bacteria
Researchers from Swiss Federal Institute of Aquatic Science and Technology found toys that can squirt water can contain pathogens, including drug-resistant superbugs, that can be deadly. (Source: the Mail online | Health)
Source: the Mail online | Health - March 27, 2018 Category: Consumer Health News Source Type: news

Novartis and GSK CEOs set out diverging strategies
Swiss group focuses on pharma as $13bn deal hands UK partner control of consumer unit (Source: FT.com - Drugs and Healthcare)
Source: FT.com - Drugs and Healthcare - March 27, 2018 Category: Pharmaceuticals Source Type: news

Novartis sells stake in consumer business to GSK for $13bn
Swiss group’s new chief sheds consumer health unit to focus on pharmaceuticals (Source: FT.com - Drugs and Healthcare)
Source: FT.com - Drugs and Healthcare - March 27, 2018 Category: Pharmaceuticals Source Type: news

Novartis sells stake in consumer unit to GSK for $13bn
Swiss group’s new chief sheds health business to focus on pharmaceuticals (Source: FT.com - Drugs and Healthcare)
Source: FT.com - Drugs and Healthcare - March 27, 2018 Category: Pharmaceuticals Source Type: news

Invitation to Roche ’s First Quarter Sales 2018 Audio Webcast and Conference Call
Roche will publish its Sales Results for the 1st Quarter of 2018 prior to the opening of the Swiss Stock Exchange on Thursday April 26th, 2018. (Source: Roche Investor Update)
Source: Roche Investor Update - March 27, 2018 Category: Pharmaceuticals Source Type: news

Novartis sells stake in joint venture to GSK for $13bn
Move to shed consumer health unit by Swiss group’s new CEO aims at focusing business (Source: FT.com - Drugs and Healthcare)
Source: FT.com - Drugs and Healthcare - March 27, 2018 Category: Pharmaceuticals Source Type: news

Roche's Tecentriq cocktail adds to lung cancer survival success
ZURICH (Reuters) - Roche's Tecentriq immunotherapy combined with other drugs boosted lung cancer patients' survival versus an older cocktail, the Swiss company said as it seeks an edge on Merck and Bristol-Myers Squibb. (Source: Reuters: Health)
Source: Reuters: Health - March 26, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

Roche's Tecentriq cocktail notches another lung cancer success
ZURICH (Reuters) - Roche's immunotherapy Tecentriq combined with other drugs boosted lung cancer patients' survival versus an older cocktail, the Swiss company's latest trial success as it seeks an edge on Merck and Bristol-Myers Squibb. (Source: Reuters: Health)
Source: Reuters: Health - March 26, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

Roche's Tecentriq cocktail helps lung cancer patients live longer
ZURICH (Reuters) - Swiss drugmaker Roche's immunotherapy Tecentriq combined with other medicines helped people with advanced lung cancer live longer, compared to patients receiving an older drug combination, the company said in a statement on Monday. (Source: Reuters: Health)
Source: Reuters: Health - March 26, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

ELCC 2018: Heine H. Hansen award given to Fabrice Barlesi
(European Society for Medical Oncology) The European Society for Medical Oncology (ESMO) and the International Association for the Study of Lung Cancer (IASLC) have announced that the 2018 Heine H. Hansen (HHH) Award will be given to Fabrice Barlesi. The award will be presented at ELCC 2018 (European Lung Cancer Congress), held April 11-14 in Geneva, Switzerland. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - March 26, 2018 Category: Cancer & Oncology Source Type: news

Novartis touts U.S. filing plans for MS drug as patent losses loom
ZURICH (Reuters) - Novartis plans to file its BAF312 multiple sclerosis drug for U.S. approval within weeks, the Swiss drugmaker said on Friday, as it seeks to refresh its portfolio of neurological medicines that is about to be hit by patent losses. (Source: Reuters: Health)
Source: Reuters: Health - March 22, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

Medical News Today: How a novel protein may combat cancer
A Swiss team recently discovered a new tumor-suppressing protein. It may help to diagnose liver cancer earlier and could play a role in future treatments. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - March 22, 2018 Category: Consumer Health News Tags: Cancer / Oncology Source Type: news

Global Digital Brand Manager
Location: Basel, Switzerland Job Type: Full-Time Employer: Abbott In this role you define and manage the business/marketing strategy and improve continuously the results of our digital brands and products, ensuring the marketing plan and tactics are implemented and responsively adapted to the competitive landscape with full buy-in and collaboration of the affiliates, leading to the commercial success of our digital brands and products. (Source: eHealth News EU)
Source: eHealth News EU - March 21, 2018 Category: Information Technology Tags: Featured Jobs Source Type: news

Roche's Tecentriq notches third cancer cocktail trial win
ZURICH (Reuters) - Roche's immunotherapy Tecentriq on Tuesday racked up a third trial win in combination with other cancer drugs, a boost for the Swiss drugmaker as it seeks to muscle in on space dominated by Merck and Bristol-Myers Squibb. (Source: Reuters: Health)
Source: Reuters: Health - March 20, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

Roche says Tecentriq, chemo cut risk of death in type of lung cancer
ZURICH (Reuters) - Roche said on Tuesday a late-stage study showed the Swiss drugmaker's immunotherapy Tecentriq plus chemotherapy cut the risk of disease worsening or death in first-line treatment of people with a type of advanced lung cancer. (Source: Reuters: Health)
Source: Reuters: Health - March 20, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

European Lung Cancer Congress 2018
(International Association for the Study of Lung Cancer) Geneva, Switzerland - Around 2,300 participants from across the world will meet in Geneva at the eighth European Lung Cancer Congress (ELCC 2018, 11-14 April 2018) to learn about and discuss the latest research in the field of lung cancer. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - March 20, 2018 Category: International Medicine & Public Health Source Type: news

LSD blurs line between ourselves and others, study finds
Drugs targeting similar brain networks as LSD could help with a variety of mental disordersApart from the wide-eyed bike ride home from the lab, his neighbour turning into a witch, the threatening behaviour of his furniture and the futile battle to save his ego from collapse, Dr Albert Hofmann appeared to enjoy his first trip on LSD.Now, 75 years after the Swiss chemist witnessed the full effects of his psychedelic invention, scientists have discovered fresh details of how the drug affects the brain. Scans of healthy volunteers show that less than half the dose that left Hofmann cowering on his sofa makes a person ’s...
Source: Guardian Unlimited Science - March 19, 2018 Category: Science Authors: Ian Sample Science editor Tags: Science Drugs Source Type: news

J & J gets $2.1B offer to sell Lifescan glucometer business
Platinum Equity, a Los Angeles-based global investment firm focused on  mergers, acquisitions, and operations, has made a binding offer to acquire Johnson& Johnsons'Chesterbrook, Pennsylvania and Zug, Switzerland-based LifeScan business, which sells the OneTouch line of connected and non-connected glucometers. Platinum Equity will pay $2.1 billion for the business, which reported $1.5 billion in net revenue last year. (Source: mobihealthnews)
Source: mobihealthnews - March 16, 2018 Category: Information Technology Source Type: news

New understanding of parasite biology might help stop malaria transmission
(Swiss Tropical and Public Health Institute) Researchers at the Swiss Tropical and Public Health Institute made an important step toward deeper understanding of how malaria blood stage parasites turn the switch to become transmissible to other humans. This knowledge is fundamental for future research aiming to interrupt malaria transmission. The results will be published on Friday, March 16, 2018, in the multidisciplinary journal Science. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - March 15, 2018 Category: Infectious Diseases Source Type: news

Toothpaste alone does not prevent dental erosion
Researchers from the University of Bern in Switzerland found that none of the nine fluoridated toothpastes they analysed completely prevent enamel loss despite regular brushing. (Source: the Mail online | Health)
Source: the Mail online | Health - March 14, 2018 Category: Consumer Health News Source Type: news

Donors pledge over US$15 million to WHO ’s Contingency Fund for Emergencies
27 March 2018 – Donors have pledged an additional US$15.3 million to support quick action by the World Health Organization to tackle disease outbreaks and humanitarian health crises through its emergency response fund in 2018, the Contingency Fund for Emergencies (CFE). Canada, Denmark, Estonia, Germany, the Republic of Korea, Kuwait, Luxembourg, Malta, Netherlands, Norway, and the United Kingdom of Great Britain and Northern Ireland announced contributions ranging from US$20,000 to US$5.6 million at a conference hosted at WHO headquarters in Geneva, Switzerland on Monday (March 26) – increasing CFE funding lev...
Source: WHO news - March 14, 2018 Category: International Medicine & Public Health Tags: emergencies [subject], emergency preparedness, crises, emergency preparedness, health financing [subject], health economics, health systems financing Source Type: news

Donors pledge over US$ 15 million to WHO ’s Contingency Fund for Emergencies
Donors have pledged an additional US$15.3 million to support quick action by the World Health Organization to tackle disease outbreaks and humanitarian health crises through its emergency response fund in 2018, the Contingency Fund for Emergencies (CFE). Canada, Denmark, Estonia, Germany, the Republic of Korea, Kuwait, Luxembourg, Malta, Netherlands, Norway, and the United Kingdom of Great Britain and Northern Ireland announced contributions ranging from US$20,000 to US$5.6 million at a conference hosted at WHO headquarters in Geneva, Switzerland on Monday (March 26) – increasing CFE funding levels to US$23 million. (Source: WHO news)
Source: WHO news - March 14, 2018 Category: International Medicine & Public Health Tags: emergencies [subject], emergency preparedness, crises, emergency preparedness, health financing [subject], health economics, health systems financing Source Type: news

Medartis IPO funds slated to support expansion
Swiss medtech company Medartis is reportedly planning to expand into the U.S. market and continue investing in Germany with the funds from its recently-announced initial public offering. Medartis announced yesterday that its IPO could include up to 2.84 million new shares of common stock priced at 44 – 54 Swiss francs apiece. That would generate proceeds of 123.7 million francs – or nearly $131 million. Taking into account the 15% over-allotment option, Medartis could bring in 142.5 million francs, or $151 million. The company makes fixation products designed to treat small-bone fractures and osteotomies in the...
Source: Mass Device - March 13, 2018 Category: Medical Devices Authors: Sarah Faulkner Tags: Implants Initial Public Offering (IPO) Orthopedics Wall Street Beat medartis Source Type: news

The U.S. Spends Twice As Much On Health Care As Other High-Income Countries
Health care spending in the U.S. is roughly twice that of other high-income nations — but all that extra money isn’t leading to better health, according to a new analysis published in JAMA. A group of researchers compared data from the U.S. and 10 other high-income countries: the United Kingdom, Canada, Germany, Australia, Japan, Sweden, France, the Netherlands, Switzerland and Denmark. They found that spending in the U.S. far outpaces that in other nations. Health care accounts for almost 18% of the U.S.’s GDP, compared to 9.6% to 12.4% in the other developed countries, the paper says. But, contrary to ...
Source: TIME: Health - March 13, 2018 Category: Consumer Health News Authors: Jamie Ducharme Tags: Uncategorized Health Care healthytime onetime Source Type: news

Roche CEO says new drugs will offset biosimilar incursions
ZURICH (Reuters) - Swiss drugmaker Roche will be able to compensate or overcompensate for falling revenue from patent-expired drugs facing competition from rivals' copies through its new medicines, Chief Executive Severin Schwan said on Tuesday. (Source: Reuters: Health)
Source: Reuters: Health - March 13, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

Roche Names Pao as Swiss R & D Head After Reed Exits Roche Names Pao as Swiss R & D Head After Reed Exits
Swiss drugmaker Roche said it will put a cancer specialist at the helm of its Swiss-based research efforts in April, after the scientist who led the unit for five years resigned for personal reasons.Reuters Health Information (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - March 9, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Novartis, U.S. Partner Plan Remote Trials to Boost Participation Novartis, U.S. Partner Plan Remote Trials to Boost Participation
Novartis plans up to 10 clinical trials over three years using a U.S. partner's mobile technology to help free patients from burdensome hospital trips as the Swiss drugmaker aims to boost study participation and cut costs.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - March 8, 2018 Category: Consumer Health News Tags: Family Medicine/Primary Care News Source Type: news

Roche names Pao as Swiss R & D head after Reed exits
ZURICH (Reuters) - Swiss drugmaker Roche said it will put a cancer specialist at the helm of its Swiss-based research efforts in April, after the scientist who led the unit for five years resigned for personal reasons. (Source: Reuters: Health)
Source: Reuters: Health - March 8, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

Roche names Pao head of drugs research and early development
ZURICH (Reuters) - Swiss drugmaker Roche named U.S. cancer expert William Pao head of its Pharma Research and Early Development (pRED) business after John Reed decided to leave for what it called personal reasons. (Source: Reuters: Health)
Source: Reuters: Health - March 8, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

New Series: Women on the Rise in Global Health
March 08, 2018This International Women's Day, we're launching a new series that explores why there aren ’t more women at the top in global health—yet.Every day I get to work side-by-side with smart, creative, tenacious people.IntraHealth International is full them. And, like at a lot of global health organizations, most of them are women.Women make up75% of the health workforce in many countries, but hold only 25% of leadership roles. And while up to 84% of global health students are women, they holdonly 24% of global health faculty positions and a quarter of directorships in global health centers.So we ’...
Source: IntraHealth International - March 7, 2018 Category: International Medicine & Public Health Authors: mnathe Source Type: news

Novartis, U.S. partner plan remote trials to boost participation
ZURICH (Reuters) - Novartis plans up to 10 clinical trials over three years using a U.S. partner's mobile technology to help free patients from burdensome hospital trips as the Swiss drugmaker aims to boost study participation and cut costs. (Source: Reuters: Health)
Source: Reuters: Health - March 7, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

WHO's First Global Conference on Air Pollution and Health
October 30-November 1, 2018; Geneva, Switzerland. (Source: PHPartners.org)
Source: PHPartners.org - March 5, 2018 Category: International Medicine & Public Health Source Type: news

Santhera's Raxone shows no efficacy benefit in MS study
ZURICH (Reuters) - Santhera Pharmaceuticals said on Monday a study of its medicine Raxone in primary progressive multiple sclerosis showed no difference between the treatment and placebo groups in disease progression, another setback for the Swiss drug company. (Source: Reuters: Health)
Source: Reuters: Health - March 5, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

UCLA pediatrician inspires humanism in young doctors
Dr. Lee Miller ’s journey began, as many do, with a train ride. Thirty years ago, he was a UCLA assistant professor traveling from Philadelphia to New York. After threading his way through the crowded aisles of every car, he eyed the last three vacant seats in the caboose.“I chose a fortuitous seat next to an elderly gentleman from Shanghai,” Miller recalled recently in a special address to UCLA medical students. “He was a pediatrician teaching students, just like me.”The ride passed quickly as the older physician recounted stories about his work in global health. When the two exchanged busine...
Source: UCLA Newsroom: Health Sciences - March 3, 2018 Category: Universities & Medical Training Source Type: news

Biogen, AbbVie pull multiple sclerosis drug from market amid safety concerns
A multiple sclerosis treatment jointly sold by Biogen and AbbVie has been pulled from the market following reports that some patients who received the drug developed brain disorders. The drug, a self-administered injection called Zinbryta, is sold by Cambridge-based Biogen (Nasdaq: BIIB) in the E.U., Switzerland and Canada, and by Chicago-AbbVie (NYSE: ABBV) in the U.S. When the FDA approved Zinbryta in 2016, the agency included a so-called black box warning, stating that the drug can cause serious… (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - March 2, 2018 Category: American Health Authors: Max Stendahl Source Type: news

Snow, High Winds Paralyze European Airports, Claim Lives
GENEVA (AP) — An extreme cold snap across Europe claimed more lives, forced the closure of airports in Scotland, Switzerland, France and Ireland and left hundreds of drivers stranded on snowy highways Thursday. Heavy snow and high winds halted all flights in and out of Dublin Airport, with authorities saying they are unlikely to resume until Saturday. Irish Rail said no trains are likely to run until Saturday. Forecasters said a new storm is brining blizzards, 100 kph (60 mph) winds, freezing rain and thunderstorms to Ireland, southwestern England and Wales later Thursday. It predicted zero visibility and deep pocket...
Source: JEMS: Journal of Emergency Medical Services News - March 1, 2018 Category: Emergency Medicine Authors: Jamey Keaten and Frank Jordans, Associated Press Tags: Major Incidents News Source Type: news

Citywide cluster randomized trial to restore blighted vacant land and its effects on violence, crime, and fear - Branas CC, South E, Kondo MC, Hohl BC, Bourgois P, Wiebe DJ, Macdonald JM.
Vacant and blighted urban land is a widespread and potentially risky environmental condition encountered by millions of people on a daily basis. About 15% of the land in US cities is deemed vacant or abandoned, an area roughly the size of Switzerland. In a... (Source: SafetyLit)
Source: SafetyLit - March 1, 2018 Category: International Medicine & Public Health Tags: Community-Based Prevention Source Type: news

Cipla's U-turn: Happily ever after?
In a foes-turn-friends move announced on February 27, the Mumbai-based drug maker announced that it will partner Swiss biotech company Roche to promote Actemra and Syndyma. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - March 1, 2018 Category: Pharmaceuticals Source Type: news

Medartis plans Swiss IPO
Swiss medtech company Medartis Holding yesterday revealed plans for an initial public offering on the SIX Swiss Exchange slated for the first half of this year. The company produces fixation products designed for treating small-bone fractures and osteotomies in the lower and upper extremities and the craniomaxiofacial region. All device production is managed in-house at its facilities in Basel, Sweden. Medartis was founded in 1997, sells products in 44 different countries including the US, Japan, the UK, France, Germany, Switzerland, Australia and Brazil. “The planned IPO will mark an important milestone in the devel...
Source: Mass Device - February 28, 2018 Category: Medical Devices Authors: Fink Densford Tags: Business/Financial News Initial Public Offering (IPO) Orthopedics Wall Street Beat medartis Source Type: news

Brexit is an opportunity to forge a stronger European Research Area, according to new consultation
The European Research Area should be strengthened and broadened as part of the Brexit process, to increase scientific collaboration across member states and associated countries such as the UK, Norway and Switzerland, according to a new report from Wellcome. The Future Partnership Project report [PDF 641KB], based on consultations with over 200 UK and European scientists and policy makers, lays out the first concrete set of recommendations of how greater scientific collaboration could be achieved after Brexit. It recommends a Brexit deal that: Enables the UK to influence, pay into and access European research fu...
Source: News from STM - February 28, 2018 Category: Databases & Libraries Authors: STM Publishing News Tags: European Featured Source Type: news